Third dose of mRNA-1273 vaccine induces serologic response in 49 percent of kidney recipients who did not respond after two doses<\/em><\/p>\n<\/h3>\n <\/b><\/p>\n <\/b><\/p>\n WEDNESDAY, July 28, 2021 (HealthDay News) — A third dose of the mRNA-1273 vaccine induces a serologic response in 49 percent of kidney transplant recipients who did not respond after receiving two doses, according to a research letter published online July 23 in the Journal of the American Medical Association<\/em>.<\/p>\n Ilies Benotmane, M.D., from Strasbourg University Hospital in France, and colleagues examined the antibody responses of kidney transplant recipients who did not respond to two COVID-19 mRNA vaccine doses and received a third dose of the Moderna mRNA-1273 vaccine. A total of 159 kidney transplant recipients with a negative history for COVID-19 and severe acute respiratory syndrome coronavirus 2 antispike immunoglobulin (Ig)G levels <50 AU\/mL on the day of the first vaccine injection and one month after the second dose were included.<\/p>\n The researchers found that 59.7 percent of the participants had no antibody response after two doses, while 40.3 percent of patients showed a response below the positivity limit. A third dose was given at a median of 51 days after the second dose. At a median 28 days after the third dose, 49 percent of the participants had antibody levels >50 AU\/mL (median antibody titer of responders, 586 AU\/mL). Compared with patients with no antibody response after the second dose, those who had a weak response were more likely to develop an antibody response after the third dose (81.3 versus 27.4 percent, respectively).<\/p>\n “The findings in this large group of kidney transplant recipients are in accordance with other studies of solid organ transplant recipients,” the authors write.<\/p>\n Two authors disclosed financial ties to the pharmaceutical industry.<\/p>\n Abstract\/Full Text (subscription or payment may be required)<\/a><\/p>\n <\/i><\/p>\n